Dr. Amin Yehya, MD
NPI: 1376720946
Total Payments
$264,071
2024 Payments
$71,893
Companies
26
Transactions
433
Medicare Patients
5,395
Medicare Billing
$494,076
Payment Breakdown by Category
Other$176,870 (67.0%)
Consulting$41,657 (15.8%)
Travel$30,222 (11.4%)
Food & Beverage$15,277 (5.8%)
Education$44.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $141,190 | 62 | 53.5% |
| Consulting Fee | $41,657 | 10 | 15.8% |
| Honoraria | $35,680 | 12 | 13.5% |
| Travel and Lodging | $30,222 | 139 | 11.4% |
| Food and Beverage | $15,277 | 207 | 5.8% |
| Education | $44.59 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $98,105 | 89 | $0 (2024) |
| Akcea Therapeutics, Inc. | $51,977 | 64 | $0 (2021) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $26,856 | 51 | $0 (2021) |
| SCPHARMACEUTICALS INC. | $26,537 | 23 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $25,788 | 31 | $0 (2024) |
| Novo Nordisk Inc | $17,052 | 11 | $0 (2024) |
| Abbott Laboratories | $5,134 | 80 | $0 (2024) |
| CVRx, Inc. | $3,519 | 20 | $0 (2024) |
| Amgen Inc. | $2,477 | 15 | $0 (2018) |
| Bayer Healthcare Pharmaceuticals Inc. | $2,148 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $71,893 | 72 | SCPHARMACEUTICALS INC. ($26,537) |
| 2023 | $44,622 | 92 | Merck Sharp & Dohme LLC ($34,559) |
| 2022 | $47,421 | 49 | Merck Sharp & Dohme LLC ($46,209) |
| 2021 | $25,634 | 27 | Merck Sharp & Dohme Corporation ($10,971) |
| 2020 | $31,042 | 43 | Akcea Therapeutics, Inc. ($16,347) |
| 2019 | $37,261 | 78 | Akcea Therapeutics, Inc. ($32,185) |
| 2018 | $2,223 | 25 | Amgen Inc. ($764.80) |
| 2017 | $3,975 | 47 | Amgen Inc. ($1,712) |
All Payment Transactions
433 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $10,268.75 | General |
| 12/05/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $424.12 | General |
| 12/05/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $288.69 | General |
| 12/05/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $234.10 | General |
| 12/05/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $228.05 | General |
| 12/04/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $775.00 | General |
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,150.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/13/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $106.91 | General |
| Category: Heart Failure | ||||||
| 11/13/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $2.58 | General |
| Category: Heart Failure | ||||||
| 11/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $2,148.00 | General |
| Category: Cardio-renal | ||||||
| 11/05/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $130.49 | General |
| Category: Cardiology | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $116.05 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Travel and Lodging | In-kind items and services | $31.21 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/23/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: Cardiology | ||||||
| 10/23/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Travel and Lodging | Cash or cash equivalent | $179.99 | General |
| Category: Cardiology | ||||||
| 10/23/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $121.35 | General |
| Category: Cardiology | ||||||
| 08/27/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: Cardiology | ||||||
| 08/27/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $140.00 | General |
| Category: Cardiology | ||||||
| 08/27/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Travel and Lodging | Cash or cash equivalent | $93.80 | General |
| Category: Cardiology | ||||||
| 08/27/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $6.37 | General |
| Category: Cardiology | ||||||
| 07/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $124.92 | General |
| 07/11/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Cardiology | ||||||
| 07/11/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $129.44 | General |
| Category: Cardiology | ||||||
| 07/11/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Travel and Lodging | Cash or cash equivalent | $25.06 | General |
| Category: Cardiology | ||||||
| 06/17/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,494 | 2,095 | $309,787 | $120,178 |
| 2022 | 15 | 1,696 | 2,586 | $299,233 | $118,373 |
| 2021 | 19 | 1,420 | 2,292 | $336,474 | $139,184 |
| 2020 | 17 | 785 | 1,537 | $292,537 | $116,341 |
Total Patients
5,395
Total Services
8,510
Medicare Billing
$494,076
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 162 | 376 | $68,318 | $27,220 | 39.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 96 | 251 | $56,428 | $23,745 | 42.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 425 | 440 | $61,950 | $22,394 | 36.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 104 | 176 | $47,404 | $18,543 | 39.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 47 | 51 | $18,824 | $7,032 | 37.4% |
| 93750 | Evaluation of lower heart chamber assist device | Facility | 2023 | 18 | 96 | $8,202 | $2,954 | 36.0% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2023 | 27 | 28 | $7,186 | $2,837 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 39 | $6,201 | $2,412 | 38.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 16 | 16 | $5,674 | $2,154 | 38.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 280 | 310 | $5,580 | $1,850 | 33.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $4,032 | $1,550 | 38.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 24 | $3,688 | $1,509 | 40.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 14 | 14 | $3,688 | $1,480 | 40.1% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 62 | 67 | $3,845 | $1,288 | 33.5% |
| 93264 | Remote monitoring of pulmonary artery pressure sensor, up to 30 days | Facility | 2023 | 29 | 36 | $2,539 | $979.16 | 38.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 14 | 14 | $2,489 | $841.69 | 33.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 16 | $1,928 | $770.50 | 40.0% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 26 | 28 | $707.00 | $275.80 | 39.0% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 58 | 63 | $403.00 | $149.80 | 37.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 24 | 24 | $432.00 | $109.82 | 25.4% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 11 | 11 | $269.00 | $82.08 | 30.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 89 | 323 | $67,830 | $25,537 | 37.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 124 | 331 | $52,629 | $23,176 | 44.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 349 | 381 | $57,150 | $20,527 | 35.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 61 | 114 | $25,536 | $12,201 | 47.8% |
About Dr. Amin Yehya, MD
Dr. Amin Yehya, MD is a Advanced Heart Failure and Transplant Cardiology healthcare provider based in Norfolk, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/25/2008. The National Provider Identifier (NPI) number assigned to this provider is 1376720946.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amin Yehya, MD has received a total of $264,071 in payments from pharmaceutical and medical device companies, with $71,893 received in 2024. These payments were reported across 433 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($141,190).
As a Medicare-enrolled provider, Yehya has provided services to 5,395 Medicare beneficiaries, totaling 8,510 services with total Medicare billing of $494,076. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Advanced Heart Failure and Transplant Cardiology
- Other Specialties Cardiovascular Disease, Cardiovascular Disease
- Location Norfolk, VA
- Active Since 01/25/2008
- Last Updated 05/24/2019
- Taxonomy Code 207RA0001X
- Entity Type Individual
- NPI Number 1376720946
Products in Payments
- VERQUVO (Drug) $72,592
- TEGSEDI (Drug) $50,122
- LifeVest (Device) $26,856
- FUROSCIX (Drug) $26,537
- FARXIGA (Drug) $22,950
- Ozempic (Drug) $4,650
- Barostim Neo System (Device) $3,519
- LOKELMA (Drug) $2,722
- CARDIOMEMS (Device) $2,273
- Kerendia (Drug) $2,148
- MK-1242 (Drug) $1,898
- HeartWare HVAD (Device) $1,882
- CardioMEMS HF System (Device) $880.43
- ENTRESTO (Drug) $725.62
- HeartMate (Device) $694.75
- HeartMate 3 Left Ventricular Assist Device (Device) $437.68
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $383.96
- Circulatory Support (Device) $268.96
- RESONATE (Device) $268.13
- Optimizer (Device) $231.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.